search icon
help-img

Helus pharma inc. share price

HELP
NMQ
$9.07
-$0.3
(-3.2%)
1D
Industry: Pharmaceuticals Sector: Health Care

Helus pharma inc. analyst forecast

Helus pharma inc. share price chart

Helus pharma inc. key stock metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$684.66M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.14M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.62
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.76 L
$15.15 H
$9.07

About helus pharma inc., common stock

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada. more

Industry: PharmaceuticalsSector: Health Care

Helus pharma inc. stock returns

Time FrameHELPSectorS&P500
1-Week Return-0.33%2.34%-0.24%
1-Month Return-18.4%9.5%-3.25%
3-Month Return-10.09%11.81%-2.64%
6-Month Return76.47%31.66%1.82%
1-Year Return41.51%27.87%10.44%
3-Year Return-44.66%49.15%70.89%
5-Year Return-87.27%41.03%62.31%
10-Year Return-81.99%163.18%247.43%

Helus pharma inc. financials

Mar '22Mar '23Mar '24Mar '25Mar '265YR TREND
Total Revenue167.76K251.01K-472.27K(44.68M)[{"date":"2022-03-31","value":35.52,"profit":true},{"date":"2023-03-31","value":53.15,"profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":100,"profit":true},{"date":"2026-03-31","value":-9461.61,"profit":false}]
Cost of Revenue167.76K251.01K-472.27K119.23K[{"date":"2022-03-31","value":35.52,"profit":true},{"date":"2023-03-31","value":53.15,"profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":100,"profit":true},{"date":"2026-03-31","value":25.25,"profit":true}]
Gross Profit----(44.80M)[{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true},{"date":"2026-03-31","value":null,"profit":false}]
Gross Margin----100.27%[{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true},{"date":"2026-03-31","value":100,"profit":true}]
Operating Expenses63.84M51.52M78.84M143.15M96.87M[{"date":"2022-03-31","value":44.6,"profit":true},{"date":"2023-03-31","value":35.99,"profit":true},{"date":"2024-03-31","value":55.07,"profit":true},{"date":"2025-03-31","value":100,"profit":true},{"date":"2026-03-31","value":67.67,"profit":true}]
Operating Income(63.84M)(51.52M)(78.84M)(143.15M)(141.68M)[{"date":"2022-03-31","value":-6383800000,"profit":false},{"date":"2023-03-31","value":-5151800000,"profit":false},{"date":"2024-03-31","value":-7883600000,"profit":false},{"date":"2025-03-31","value":-14314700000,"profit":false},{"date":"2026-03-31","value":-14167741300,"profit":false}]
Total Non-Operating Income/Expense(3.72M)4.38M1.38M37.83M89.06M[{"date":"2022-03-31","value":-4.18,"profit":false},{"date":"2023-03-31","value":4.92,"profit":true},{"date":"2024-03-31","value":1.54,"profit":true},{"date":"2025-03-31","value":42.47,"profit":true},{"date":"2026-03-31","value":100,"profit":true}]
Pre-Tax Income(67.80M)(47.74M)(78.08M)(113.61M)(57.69M)[{"date":"2022-03-31","value":-6779876000,"profit":false},{"date":"2023-03-31","value":-4774101500,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false},{"date":"2025-03-31","value":-11360927000,"profit":false},{"date":"2026-03-31","value":-5768521200,"profit":false}]
Income Taxes(167.76K)(251.01K)-(472.27K)89.37M[{"date":"2022-03-31","value":-0.19,"profit":false},{"date":"2023-03-31","value":-0.28,"profit":false},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":-0.53,"profit":false},{"date":"2026-03-31","value":100,"profit":true}]
Income After Taxes(67.63M)(47.49M)(78.08M)(113.14M)(147.05M)[{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false},{"date":"2025-03-31","value":-11313700000,"profit":false},{"date":"2026-03-31","value":-14705389500,"profit":false}]
Income From Continuous Operations(67.63M)(47.49M)(78.08M)(113.14M)(147.05M)[{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false},{"date":"2025-03-31","value":-11313700000,"profit":false},{"date":"2026-03-31","value":-14705389600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true},{"date":"2026-03-31","value":"-","profit":true}]
Net Income(67.63M)(47.49M)(78.08M)(113.14M)(147.05M)[{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false},{"date":"2025-03-31","value":-11313700000,"profit":false},{"date":"2026-03-31","value":-14705389600,"profit":false}]
EPS (Diluted)(15.36)(9.74)(9.41)(5.59)(4.23)[{"date":"2022-03-31","value":-1536,"profit":false},{"date":"2023-03-31","value":-974,"profit":false},{"date":"2024-03-31","value":-941,"profit":false},{"date":"2025-03-31","value":-559,"profit":false},{"date":"2026-03-31","value":-423,"profit":false}]

Helus pharma inc. ratios

Helus pharma inc. liquidity ratios

These ratios help you determine the liquidity of the company. Higher is better.

HELP
Cash Ratio 9.47
Current Ratio 10.97
Quick Ratio 10.97

Helus pharma inc. asset efficiency ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HELP
ROA (LTM) -67.58%
ROE (LTM) -74.47%

Helus pharma inc. liability ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HELP
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Helus pharma inc. valuation ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HELP
Trailing PE NM
P/S (TTM) 0.00
P/B 2.30
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

Faqs

What is Helus Pharma Inc. share price today?

Helus Pharma Inc. (HELP) share price today is $9.07

Can Indians buy Helus Pharma Inc. shares?

Yes, Indians can buy shares of Helus Pharma Inc. (HELP) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HELP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Helus Pharma Inc. be purchased?

Yes, you can purchase fractional shares of Helus Pharma Inc. (HELP) via the Vested app. You can start investing in Helus Pharma Inc. (HELP) with a minimum investment of $1.

How to invest in Helus Pharma Inc. shares from India?

You can invest in shares of Helus Pharma Inc. (HELP) via Vested in three simple steps:

  • Click on Sign Up or Invest in HELP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Helus Pharma Inc. shares

What is Helus Pharma Inc. 52-week high and low stock price?

The 52-week high price of Helus Pharma Inc. (HELP) is $15.15. The 52-week low price of Helus Pharma Inc. (HELP) is $3.76.

What is Helus Pharma Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Helus Pharma Inc. (HELP) is

What is Helus Pharma Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Helus Pharma Inc. (HELP) is 2.30

What is Helus Pharma Inc. dividend yield?

The dividend yield of Helus Pharma Inc. (HELP) is 0.00%

What is the Market Cap of Helus Pharma Inc.?

The market capitalization of Helus Pharma Inc. (HELP) is $684.66M

What is Helus Pharma Inc.'s stock symbol?

The stock symbol (or ticker) of Helus Pharma Inc. is HELP

How Can Investors Use Helus Pharma Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Helus Pharma Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Helus Pharma Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Helus Pharma Inc. shares for Indian investors?

When investing in Helus Pharma Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Helus Pharma Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Helus Pharma Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Helus Pharma Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Helus Pharma Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top